Patents by Inventor Matthew M. Lin

Matthew M. Lin has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • INHIBITING HUMAN INTEGRIN (ALPHA-4) (BETA-7)
    Publication number: 20240174632
    Abstract: Disclosed are small molecule antagonists of human ?4?7 integrin, and methods of using them to treat a number of diseases and conditions.
    Type: Application
    Filed: October 16, 2020
    Publication date: May 30, 2024
    Applicant: Morphic Therapeutic, Inc.
    Inventors: Matthew G. BURSAVICH, Dan CUI, James E. DOWLING, Kristopher N. HAHN, Bryce A. HARRISON, Fu-Yang LIN, Blaise S. LIPPA, Bruce N. ROGERS, Dawn M. TROAST, Cheng ZHONG, Kyle D. KONZE, Aleksey I. GERASYUTO, Byungchan KIM, Salma RAFI, Tyler DAY, Eugene HICKEY, Evelyne HOUANG, Robert ZAHLER
  • INHIBITORS OF (ALPHA-V)(BETA-6) INTEGRIN
    Publication number: 20240116929
    Abstract: Disclosed are small molecule inhibitors of ?v?6 integrin, and methods of using them to treat a number of specific diseases or conditions.
    Type: Application
    Filed: September 18, 2023
    Publication date: April 11, 2024
    Inventors: Bryce A. Harrison, Matthew G. Bursavich, Aleksey I Gerasyuto, Kristopher N. Hahn, Kyle D. Konze, Fu-Yang Lin, Blaise S. Lippa, Alexey A. Lugovskoy, Bruce N. Rogers, Mats A. Svensson, Dawn M. Troast
  • Methods for Treating HCV
    Publication number: 20240082245
    Abstract: The present invention features interferon-free therapies for the treatment of HCV. Preferably, the treatment is over a shorter duration of treatment, such as no more than 12 weeks. In one aspect, the treatment comprises administering at least two direct acting antiviral agents to a subject with HCV infection, wherein the treatment lasts for 12 weeks and does not include administration of either interferon or ribavirin, and said at least two direct acting antiviral agents comprise (a) Compound 1 or a pharmaceutically acceptable salt thereof and (b) Compound 2 or a pharmaceutically acceptable salt thereof.
    Type: Application
    Filed: November 3, 2023
    Publication date: March 14, 2024
    Inventors: Christine Collins, Bo Fu, Abhishek Gulati, Jens Kort, Matthew Kosloski, Yang Lei, Chih-Wei Lin, Ran Liu, Federico Mensa, Iok Chan NG, Tami Pilot-Matias, David Pugatch, Nancy S. Shulman, Roger Trinh, Rolando M. Viani, Stanley Wang, Zhenzhen Zhang
  • Method of treating allergic rhinitis by delivering medication via the nasal vestibules
    Patent number: 5972327
    Abstract: A method for treating allergic rhinitis in a patient is disclosed which comprises applying an anti-allergic rhinitis effective amount of a steroid in ointment or creme carrier to the lining of the vestibules of the patient.
    Type: Grant
    Filed: October 22, 1997
    Date of Patent: October 26, 1999
    Inventors: Matthew M. Lin, Audrey H. Lin